Literature DB >> 16505020

Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis.

Jiucheng He1, Haydee E P Bazan.   

Abstract

PURPOSE: Elimination of myofibroblasts after repair of corneal injury is essential for the maintenance of corneal transparency. In the current study, the role of platelet-activating factor (PAF) in combination with tumor necrosis factor (TNF)-alpha in corneal myofibroblast apoptosis was explored.
METHODS: Porcine corneal myofibroblasts (PCMs) were obtained from subcultured fibroblasts plated at a low density (5 cells/mm2). Mouse anti-alpha-smooth muscle actin antibody was used to identify the cell phenotype. Immunofluorescence was performed to localize PAF and TNF-alpha receptors in those cells. The reactivity of the antibodies was characterized by Western blot analysis. To induce myofibroblast apoptosis, PCMs were treated for 24 to 72 hours with methylcarbamyl-PAF (cPAF, 300 nM), a nonhydrolyzable PAF analogue, TNF-alpha (20 ng/mL), and TNF-alpha+cPAF, with or without LAU-0901 (150 nM), a novel PAF antagonist. Apoptosis was assayed by Hoechst 33258 and TUNEL staining and DNA laddering. 6-Diamidino-2-phenylindole (DAPI) was used for nuclear counterstaining. Images were recorded by fluorescence microscope.
RESULTS: Immunofluorescence with a PAF-receptor (N terminus) polyclonal antibody showed that the receptor was expressed in both plasma and nuclear membranes of myofibroblasts. TNF-alpha receptor II (TNF-RII) was localized in the cytoplasm, whereas TNF-receptor I (TNF-RI) was found in both cytoplasm and plasma membrane. Treatment with TNF-alpha for 24, 48, and 72 hours induced apoptosis in 18%, 24%, and 32%, respectively, of the myofibroblasts. Western blot analysis showed expression of single bands corresponding to the molecular weights of the receptors. Treatment with cPAF induced apoptosis in 10%, 18%, and 26% of the cells, respectively. However, treatment with both cytokines induced apoptosis in 42%, 78%, and 86%, respectively, of the cells, demonstrating a synergistic action between PAF and TNF-alpha. Blocking the PAF receptor with LAU-0901 inhibited the synergistic effect induced by PAF.
CONCLUSIONS: Corneal myofibroblasts express a PAF receptor in the nuclear membrane, and they also express TNF-RI and RII. The synergistic effect on myofibroblast apoptosis by PAF and TNF-alpha suggests that during corneal stromal wound healing, PAF acting in conjunction with other cytokines could play an important role in eliminating these cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505020     DOI: 10.1167/iovs.05-0581

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia.

Authors:  Ludmila Belayev; Larissa Khoutorova; Kristal Atkins; William C Gordon; Julio Alvarez-Builla; Nicolas G Bazan
Journal:  Exp Neurol       Date:  2008-08-28       Impact factor: 5.330

Review 2.  Omega-3 fatty acids in dry eye and corneal nerve regeneration after refractive surgery.

Authors:  Jiucheng He; Haydee E P Bazan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-03       Impact factor: 4.006

Review 3.  Role of platelet-activating factor in cell death signaling in the cornea: A review.

Authors:  Salomon Esquenazi; Haydee E P Bazan
Journal:  Mol Neurobiol       Date:  2010-04-30       Impact factor: 5.590

4.  Expressions of tumor necrosis factor-α, its receptor I, II and receptor-associated factor 2 in the porcine corpus luteum during the estrous cycle and early pregnancy.

Authors:  Chie Suzuki; Koji Yoshioka; Manabu Yamada; Toru Miyamoto; Noboru Manabe
Journal:  Vet Res Commun       Date:  2013-09-22       Impact factor: 2.459

5.  Signaling cross talk between growth hormone (GH) and insulin-like growth factor-I (IGF-I) in pancreatic islet β-cells.

Authors:  Fanxin Ma; Zhe Wei; Chunwei Shi; Yan Gan; Jia Lu; Stuart J Frank; James Balducci; Yao Huang
Journal:  Mol Endocrinol       Date:  2011-10-27

6.  LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat.

Authors:  Ludmila Belayev; Larissa Khoutorova; Kristal Atkins; Alice Cherqui; Julio Alvarez-Builla; Nicolas G Bazan
Journal:  Brain Res       Date:  2008-12-03       Impact factor: 3.252

Review 7.  Significance of lipid mediators in corneal injury and repair.

Authors:  Sachidananda Kenchegowda; Haydee E P Bazan
Journal:  J Lipid Res       Date:  2009-11-03       Impact factor: 5.922

8.  Epidermal growth factor synergism with TGF-beta1 via PI-3 kinase activity in corneal keratocyte differentiation.

Authors:  Jiucheng He; Haydee E P Bazan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07       Impact factor: 4.799

9.  Synergism in the repression of COX-2- and TNFalpha-induction in platelet activating factor-stressed human neural cells.

Authors:  Anja Boetkjaer; Merete Boedker; Jian-Guo Cui; Yuhai Zhao; Walter J Lukiw
Journal:  Neurosci Lett       Date:  2007-08-31       Impact factor: 3.046

10.  Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke.

Authors:  Ludmila Belayev; Tiffany N Eady; Larissa Khoutorova; Kristal D Atkins; Andre Obenaus; Marta Cordoba; Juan J Vaquero; Julio Alvarez-Builla; Nicolas G Bazan
Journal:  Transl Stroke Res       Date:  2011-10-27       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.